Wuyts Stephanie C M, Torensma Bart, Schellekens Arnt F A, Kramers Cornelis Kees
Pharmacy Department, Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium.
Research Group Clinical Pharmacology and Clinical Pharmacy, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
J Clin Med. 2023 Jun 27;12(13):4296. doi: 10.3390/jcm12134296.
The persisting use of opioids following bariatric surgery has emerged as a prevalent complication, heightening the probability of opioid-related harm (ORM), such as opioid-related fatalities and prescription opioid use disorder (OUD). A comprehensive review of PubMed literature from 1990 to 2023 was conducted to pinpoint physiological influences on postoperative ORM. As a result, we found that patients undertaking bariatric operations often exhibit an inherently higher risk for substance use disorders, likely attributable to genetic predisposition and related neurobiological changes that engender obesity and addiction-like tendencies. Furthermore, chronic pain is a common post-bariatric surgery complaint, and the surgical type impacts opioid needs, with increased long-term opioid use after surgeries. Additionally, the subjective nature of pain perception in patients with obesity can distort pain reporting and the corresponding opioid prescription both before and after surgery. Furthermore, the postoperative alterations to the gastrointestinal structure can affect the microbiome and opioid absorption rates, resulting in fluctuating systemic exposure to orally ingested opioids. The prospect of ORM development post-bariatric surgery appears amplified due to a preexisting susceptibility to addictive habits, surgically induced pain, modified gut-brain interaction and pain management and the changed pharmacokinetics post-surgery. Further research is warranted to clarify these potential risk variables for ORM, specifically OUD, in the bariatric population.
减肥手术后持续使用阿片类药物已成为一种普遍的并发症,增加了阿片类药物相关危害(ORM)的可能性,如阿片类药物相关死亡和处方阿片类药物使用障碍(OUD)。对1990年至2023年PubMed文献进行了全面综述,以确定对术后ORM的生理影响。结果,我们发现接受减肥手术的患者通常本身就有较高的物质使用障碍风险,这可能归因于遗传易感性以及导致肥胖和成瘾倾向的相关神经生物学变化。此外,慢性疼痛是减肥手术后常见的主诉,手术类型会影响阿片类药物的需求,手术后长期使用阿片类药物的情况会增加。此外,肥胖患者疼痛感知的主观性会扭曲手术前后的疼痛报告和相应的阿片类药物处方。此外,胃肠道结构的术后改变会影响微生物群和阿片类药物吸收率,导致口服阿片类药物的全身暴露量波动。由于存在成瘾习惯易感性、手术引起的疼痛、改变的肠-脑相互作用和疼痛管理以及术后药代动力学变化,减肥手术后发生ORM的可能性似乎更大。有必要进行进一步研究,以阐明减肥人群中这些潜在的ORM风险变量,特别是OUD。